About the Expert
Luciana Borio is a senior fellow for global health at the Council on Foreign Relations (CFR). She also is a venture partner at Arch, a venture capital firm that provides seed/early-stage venture capital for technology firms in information technology, life sciences, and physical sciences. Dr. Borio specializes in biodefense, emerging infectious diseases, medical product development, and complex public health emergencies.
Dr. Borio was formerly (2019-2021) the vice president at In-Q-Tel, an independent, non-profit, strategic investment firm that works to identify, adapt, and deliver innovative technology solutions to support the missions of the United States Intelligence Community. She also previously served as director for medical and biodefense preparedness at the National Security Council (2017-2019), where she coordinated the response to the Ebola epidemic in West Africa, efforts to combat antimicrobial resistance, and the development of an Executive Order to modernize America's influenza vaccines. Prior to that, she served as the acting chief scientist of the U.S. Food and Drug Administration (2015-2017), and the assistant commissioner for Counterterrorism Policy of the FDA (2010-2017). Dr. Borio is an adjunct assistant professor of medicine at Johns Hopkins University (2003-present).
Dr. Borio obtained her MD from George Washington University, completed a residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center, and a combined fellowship in infectious diseases at Johns Hopkins and critical care at the National Institutes of Health. She continues to practice medicine, part-time, at Johns Hopkins.
- ARCH Venture Partners, venture partner
- CEPI, Scientific Advisory Board, member
- Eagle Pharmaceuticals, board member
- Goldman Sachs, consultant
- Insulet, board member
- Johns Hopkins University School of Medicine, assistant professor of medicine (part-time)
- Noblis, board of trustees, member
- The Clorox Company, Scientific Advisory Board, member